about
American Society of Clinical Oncology Expert Statement: collection and use of a cancer family history for oncology providersAcceptability of prophylactic salpingectomy with delayed oophorectomy as risk-reducing surgery among BRCA mutation carriers.Evaluation of clinical criteria for the identification of Lynch syndrome among unselected patients with endometrial cancer.Molecular pathogenesis of endometrial cancers in patients with Lynch syndromeOutcomes of screening endometrial cancer patients for Lynch syndrome by patient-administered checklistConsequences of universal MSI/IHC in screening ENDOMETRIAL cancer patients for Lynch syndrome.Germline loss-of-function mutations in LZTR1 predispose to an inherited disorder of multiple schwannomasPrimary peritoneal cancer after bilateral salpingo-oophorectomy in two patients with Lynch syndromeMicroscopic and early-stage ovarian cancers in BRCA1/2 mutation carriers: building a model for early BRCA-associated tumorigenesis.Satisfaction with ovarian carcinoma risk-reduction strategies among women at high risk for breast and ovarian carcinoma.A clinical perspective on genetic counseling and testing during end of life care for women with recurrent progressive ovarian cancer: opportunities and challenges.Testing women with endometrial cancer to detect Lynch syndrome.Is it all Lynch syndrome?: An assessment of family history in individuals with mismatch repair-deficient tumors.Prospective multicenter randomized intermediate biomarker study of oral contraceptive versus depo-provera for prevention of endometrial cancer in women with Lynch syndrome.What women with ovarian cancer think and know about genetic testingEndometrial and ovarian cancer in women with Lynch syndrome: update in screening and prevention.Evaluating women with ovarian cancer for BRCA1 and BRCA2 mutations: missed opportunities.Genetic counseling considerations in the evaluation of families for Lynch syndrome--a review.Is low-grade serous ovarian cancer part of the tumor spectrum of hereditary breast and ovarian cancer?Genetic testing by cancer site: uterus.Genetic predisposition in gynecologic cancers.Obstetrics/gynecology residents' knowledge of hereditary breast and ovarian cancer and Lynch syndrome.Preventing future cancers by testing women with ovarian cancer for BRCA mutations.Incidental germline variants in 1000 advanced cancers on a prospective somatic genomic profiling protocolDecisions about prenatal testing for chromosomal disorders: perceptions of a diverse group of pregnant women.Germline multi-gene hereditary cancer panel testing in an unselected endometrial cancer cohort.Prophylactic bilateral salpingo-oophorectomy compared with surveillance in women with BRCA mutations.Gynecologic cancer as a "sentinel cancer" for women with hereditary nonpolyposis colorectal cancer syndrome.Cost-effectiveness analysis of prevention strategies for gynecologic cancers in Lynch syndrome.Clearer Picture of PMS2-Associated Lynch Syndrome Is EmergingReply to D. Braun et alLifetime Cancer Risks of PTEN Mutation Carriers--LetterExpanding the Criteria forBRCAMutation Testing in Breast Cancer SurvivorsEndometrial Cancer in an AdolescentIn ReplyProspective Determination of Prevalence of Lynch Syndrome in Young Women With Endometrial CancerPathologic features of endometrial carcinoma associated with HNPCCProphylactic Surgery to Reduce the Risk of Gynecologic Cancers in the Lynch SyndromeWomen With Synchronous Primary Cancers of the Endometrium and Ovary: Do They Have Lynch Syndrome?
P50
Q30416965-7A3DC59C-A0FA-468A-B44D-C440A7FC3260Q33668934-9F6CE238-B12D-4A9D-95BF-425621BF5A21Q33874719-4DDBBDE0-57AF-46B0-B3C0-67A0A9208EF8Q33996492-932A4582-2E78-45FC-98BF-4838901D74ACQ34008620-91FEC2BB-A5C8-4458-8459-8D940291BC81Q34017044-4CF4CB44-485F-40AE-92DB-AF6F5F7CB25EQ34393793-B9773AEB-1F66-491C-B7F1-8B98EBDD681AQ34600647-F19EC1D9-1FBD-498C-AF52-7AB77C3B7533Q34625221-7D211822-1869-41D9-B75A-AF8269805D7BQ34626842-BB191DE4-E2D1-42DE-8DAB-4AFE2AD64961Q34856782-A3A302C9-D822-448F-8F18-AAAC458541BEQ36920374-EA4EF5CD-2605-42A4-9D59-798B69247F02Q37073606-933F7C79-7F2C-45D2-AB26-5034DDD641FEQ37080313-65C87343-8995-4D54-BB65-0F43BB0719C3Q37103527-2841E492-B99A-4E7B-9F57-CA72BCA73649Q37288004-CC2F1791-BE7F-4F47-AB25-812183EE5915Q37629639-D2B7BBA1-6E5B-4145-9498-095632BA09B4Q37798758-8F9914E3-7BB3-46B6-B89D-B2142CCCB62DQ37815309-E78D017C-6474-4B08-932A-7899225FE4A4Q38030752-7A0CBB5C-DD17-4449-9F2D-7A18EAB23EA0Q39023780-D90D1CCB-CA85-4970-A54B-CCECF4E3C388Q39897235-D01654B4-89A4-4EC4-AF7A-1E43BF1D0855Q39937374-0617FFE4-1084-4BD3-8032-2F3D07281FE0Q40568462-58554067-CDD8-4D93-84E5-A51B69725856Q41739512-676CB7BA-0769-4F8C-AE29-2802F6B40D96Q42619703-62944D1D-16E8-4359-B54A-41B3C07D4443Q43424801-1AC29AF2-4B71-49DA-9313-3AE36F9834D7Q50776571-EE3485CF-3EB1-49D6-AE17-5DD4F89A7FBCQ51117431-45B9E09B-AB71-4232-BE43-00DB7F015CF4Q60167322-10A91E5E-3BB6-4BBC-AEFB-A7F0242EAF39Q60167328-C805E800-C0CD-4753-8C16-A8619D198B78Q60167331-D72A5A6E-8003-4D25-BB31-21F08993767CQ60167338-93C45122-F3E1-4ECF-AEC3-9AFA397DC74AQ60167344-E4640861-CFB8-46D6-A4DE-D86F78F41BA9Q60167346-84E713F5-DFC0-46E8-B3AE-1C313E58E58FQ60167347-3539D6E5-3473-422A-AE4D-3D38DA9637F5Q60167348-E0B442CD-E4FE-4AFB-809A-2BCF07F0DC4DQ60167349-53A5927E-69CC-46B7-A21B-BFF635260268Q60167351-49C0A12E-36E1-43FB-913C-60782A7A9F40
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Molly S Daniels
@nl
Molly S Daniels
@sl
Molly S. Daniels
@en
Molly S. Daniels
@es
type
label
Molly S Daniels
@nl
Molly S Daniels
@sl
Molly S. Daniels
@en
Molly S. Daniels
@es
prefLabel
Molly S Daniels
@nl
Molly S Daniels
@sl
Molly S. Daniels
@en
Molly S. Daniels
@es
P106
P1153
55967818900
P21
P31
P496
0000-0002-5093-5539